Intraindividual Tumor Heterogeneity in Neuroendocrine Tumors Revealed with 18F-FDG and 68Ga-DOTA-TATE PET/CTEmre Demirci1*, Betül Vatankulu2, Resit Akyel2, Fuat Dede3 and Metin Halac2
- *Corresponding Author:
- Emre Demirci, M.D
Department of Nuclear Medicine
Sisli Etfal Training and Research Hospital
Tel: +90 (212) 3735000
Email: [email protected]
Received date: December 19, 2015 Accepted date: January 27, 2016 Published date: January 31, 2016
Citation: Demirci E, Vatankulu B, Akyel R, Dede F, Halac M (2016) Intraindividual Tumor Heterogeneity in Neuroendocrine Tumors Revealed with 18F-FDG and 68Ga-DOTA-TATE PET/CT. J Nucl Med Radiat Ther 7:277. doi:10.4172/2155-9619.1000277
Copyright: © 2016 Demirci E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.
68Ga-DOTA-TATE PET/CT is widely used in functional imaging of neuroendocrine tumors (NETs) and is superior to conventional somatostatin receptor scintigraphy (SRS), which is recommended for low grade NETs according to NANETS/ENETS guidelines. On the contrary 18F-FDG PET is suggested in patients with high grade NETs or when SRS is negative. However, tumor heterogeneity is a common finding along with NETs and causes differential expression of somatostatin receptor (sstr) and various FDG metabolisms. Here, we present a case where tumor heterogeneity is revealed with combined use of 18F-FDG PET/CT and 68Ga-DOTA-TATE PET/CT in the same patient and how does it influence clinical decision-making Conclusion: We here present the first report of FFF-VMAT achieving a comparable plan quality with less delivery time to that of FF-VMAT and HT in head and neck cancer. FFF-VMAT is a highly efficient and feasible option for the treatment of head and neck cancer in clinical practice.